We believe the future of mental health treatment lies in rethinking what already works. TREXAVIVE is our first step — a repurposed, precision-delivered therapy
now approved for DVA-funded use.
With a lean model, a clear market need, and a regulatory-ready pathway, Trexapharm represents a fast-moving opportunity to bring scalable impact to a stagnant space.
Key Highlights
Funded access already in motion (via DVA)
Repurposed compound strategy accelerates development
TGA-compliant, Australian-made manufacturing
Dual-mechanism platform with future indication potential
Clinician demand growing through existing partnerships
OUR MARKET FOCUS
Treatment-Resistant Depression (TRD)
PTSD (including veteran populations)
Suicidality & high-risk depressive states
These are high-need, high-cost areas that remain underserved by traditional treatments.
Discover how TREXAPHARM is redefining treatment access
Reach out for our current investor information
In Australia over
1 Million people live
with depression.
We intend to
make a difference.
OUR MODEL
Lean, clinical-first development
Real-world partnerships with prescribing clinicians
